CDC report delayed
The Washington Post says the CDC acting director delayed a report showing last winter’s COVID‑19 vaccine cut ER visits and hospitalizations by about 50% for healthy adults — a finding that rekindled debate over vaccine effectiveness and transparency. (x.com) The Post's social post drew heavy attention online — about 9,083 likes, 4,611 reposts and roughly 414k views on the platform where it was shared. (x.com)
A Centers for Disease Control and Prevention report was set for publication on March 19, 2026, and then held back after acting director Jay Bhattacharya raised objections to the study’s methods, according to reporting published on April 9. (thehill.com) The unpublished analysis said adults without major risk conditions who got the latest coronavirus shot had about 50 percent fewer emergency department visits and about 55 percent fewer hospitalizations than adults who did not get a 2025 or 2026 dose. (yahoo.com) This was not a press release or a slide deck. It was headed for the Morbidity and Mortality Weekly Report, the Centers for Disease Control and Prevention’s main scientific bulletin, which the agency uses to publish outbreak findings, vaccine studies, and public-health guidance. (cdc.gov) (beckershospitalreview.com) Bhattacharya’s reported objection was methodology. That matters because vaccine effectiveness studies are not lab tests with identical twins; they are real-world comparisons built from hospital records, test results, and vaccination histories. (cdc.gov) The Centers for Disease Control and Prevention says vaccine effectiveness means measuring how often vaccinated and unvaccinated people end up with outcomes like illness, hospitalization, or death under real-world conditions. The agency also says it uses surveillance systems, electronic health records, and prospective studies to do that work. (cdc.gov) One common design is the “test-negative” approach, which works like comparing two groups who both showed up sick enough to seek care, then checking who tested positive and who had been vaccinated. The Washington Post reported that the delayed coronavirus paper used the same basic approach that the agency has long used for respiratory viruses. (dnyuz.com) That is why critics inside and outside the agency focused on consistency. A Centers for Disease Control and Prevention paper published on February 27, 2025 used similar methods and found the 2024–2025 coronavirus vaccine cut emergency or urgent-care visits by 33 percent and hospitalizations in immunocompetent adults age 65 and older by 45 to 46 percent. (cdc.gov) The policy backdrop has also changed. Current Centers for Disease Control and Prevention guidance for the 2025–2026 season says vaccination for people age 6 months to 64 years is based on shared clinical decision-making, with the benefit judged most favorable for people at higher risk and lowest for people not at increased risk. (cdc.gov) So the fight here is not just over one unpublished table. It is over who gets to decide when a study is “good enough” to reach doctors, hospitals, and state health departments during a respiratory virus season when recommendations are already narrower than they were a few years ago. (cdc.gov 1) (cdc.gov 2) As of April 10, 2026, the report still had not appeared in the Morbidity and Mortality Weekly Report index. That leaves the public arguing over a study most people still cannot read, while the only detailed numbers in circulation are coming through news accounts of the delay itself. (cdc.gov) (reuters.com)
